Twelve-month prostate-specific antigen values and perineural invasion as strong independent prognostic variables of long-term biochemical outcome after prostate seed brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 84, Issue 4, 2012, Pages 962-967

  Ding, William ^a   Lee, John ^a   Chamberlain, David ^b   Cunningham, James ^c   Yang, Lixi ^a   Tay, Jonathan ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b Saint Mary's   (United States)

^c Carson Urology   (United States)

Author keywords

Perineural invasion; Prostate brachytherapy; Prostate cancer; Prostate specific antigen failure; PSA nadir

Indexed keywords

ANTIGENS; DISEASES; HOSPITALS; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT TREATMENT; RADIOTHERAPY;

PERINEURAL INVASION; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; PSA NADIR;

UROLOGY;

IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN; PALLADIUM; RADIOACTIVE IODINE; RADIOISOTOPE;

AGED; ARTICLE; BRACHYTHERAPY; CANCER PROGNOSIS; CANCER STAGING; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PERINEURAL INVASION; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT PLANNING; ANALYSIS OF VARIANCE; BLOOD; CANCER GRADING; CANCER INVASION; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; PROSTATE TUMOR; RADIATION DOSE; TIME; TUMOR RECURRENCE;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PALLADIUM; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84872012855     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2012.01.043     Document Type: Article

References (20)

1. Grimm PD, Blasko JC, Sylvester JE, et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I bra-chytherapy. Int J Radiat Oncol Biol Phys 2001; 51:31-40.
2. Cesaretti JA, Stone NN, Skouteris VM, et al. Brachytherapy for the treatment of prostate cancer. Cancer J 2007; 13:302-312.
3. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 2001; 58:843-848.
4. Critz FA, Williams WH, Benton JB, et al. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. J Urol 2000; 163:1085-1089.
5. Critz FA, Levinson AK, Williams WH, et al. Prostate specific antigen nadir achieved by men apparently cured of prostate cancer of radiotherapy. J Urol 1999; 161:1199-1205.
6. Zietman AL, tibbs MK, Dallow KC, et al. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol 1996; 40:1140-1150.
7. Zelefsky MJ, Shi W, Yamada Y, et al. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality. Int J Radiat Oncol Biol Phys 2009; 75:1350-1356.
8. Stock RG, Stone NN, Wesson MF, et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995; 32: 219-225.
9. Kaplan EL, Meier P. Non Parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-481.
10. Kattan MW, Potters L, Blasko JC, et al. Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. Urology 2001; 58:393-399.
11. Nickers P, Albert A, Waltregny D, et al. Prognostic value of PSA nadir <4 ng/ml within 4 months of high-dose radiotherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2006; 65: 73-77.
12. Iannuzzi CM, Stock RG, Stone NN. PSA kinetics following I-125 radioactive seed implantation in the treatment of T1-T2 prostate cancer. Radiat Oncol Invest 1999; 7:30-35.
13. D'Amico AV, Wu Y, Chen MH, et al. Perineural invasion as a predictor of biochemical outcome following radical prostatectomy for select men with clinically localized prostate cancer. J Urol 2001; 165:126-129.
14. Nelson CP, Dunn RL, Wei JT, et al. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: A tool to facilitate treatment decisions. Urologic Oncol 2003; 21: 213-218.
15. Anderson PR, Hanlon AL, Patchefsky A, et al. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/mL treated with conformal external beam radiation therapy. Int J Radiat Oncol Biol Phys 1998; 41:1087-1092.
16. Merrick GS, Butler WM, Galbreath RW, et al. Perineural invasion is not predictive of biochemical outcome following prostate brachy-therapy. Cancer J 2001; 7:404-412.
17. Wallner KE, Blasko J, Dattoli MJ. Evaluating Cancer status. Prostate brachytherapy made complicated. Seattle: Smart Medicine Press; 1997. 14.0-14.15.
18. Zietman AL, Christodouleas JP, Shipley WU. PSA bounces after neoadjuvant androgen deprivation and external beam radiation: Impact on definitions of failure. Int J Radiat Oncol Biol Phys 2005; 62: 714-718.
19. Thompson A, Keyes M, Pickles T, et al. Evaluating the Phoenix definition of biochemical failure after I-125 prostate brachytherapy: Can PSA kinetics distinguish PSA failures from PSA bounce? Int J Radiat Oncol Biol Phys 2010; 78:415-421.
20. Ciezki JP, Reddy CA, Garcia J, et al. PSA Kinetics after prostate brachytherapy: PSA bounce phenomenon and its implications for PSA doubling time. Int J Radiat Oncol Biol Phys 2006; 64:512-517.